Brief: TRACON Pharmaceuticals Gets IND Approval For Sarcoma Potential Treatment
29/08/2022 13:44
Aug 29 (Reuters) - TRACON Pharmaceuticals Inc TCON.O :
* TRACON PHARMACEUTICALS ANNOUNCES APPROVAL OF IND FOR
CTLA-4
ANTIBODY YH001 FOR THE TREATMENT OF FRONT-LINE SARCOMA PATIENTS
IN COMBINATION WITH ENVAFOLIMAB
Source text for Eikon: ID:nGNX6Jb6jr
Further company coverage: TCON.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TRACON Pharmaceuticals
See all newsBrief: TRACON Pharmaceuticals Says ENVASARC Trial ORR Is 5%, Does Not Meet 11% Endpoint
Tracon Pharmaceuticals Inc Reports Results For The Quarter Ended In March: Earnings Summary
Tracon Pharmaceuticals Inc Expected To Post A Loss Of $1.19 A Share: Earnings Preview
Tracon Pharmaceuticals Inc Expected To Post A Loss Of $1.19 A Share: Earnings Preview
Brief: Tracon Pharmaceuticals Files For Offering Of Common Stock, Pre-Funded Warrants